Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof capable of increasing the bioavailability of iron in the subject.
1. A method of treating or ameliorating iron deficiency, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a lipocalin mutein, or a fragment thereof having binding affinity to hepcidin, wherein the lipocalin mutein has the same amino acids as the mutein set forth in SEQ ID NO: 1 at two or more positions corresponding to positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 106, 125, 127, 132, and 134 of the linear polypeptide sequence of the mature hNGAL, wherein the lipocalin mutein or fragment is capable of increasing the bioavailability of iron in the subject, wherein said fragment lacks at least one of the N-terminal and/or C-terminal amino acids compared to said lipocalin mutein.
2. The method of claim 1 , wherein said composition is administered via a parenteral route or non-parenteral route.
3. The method of claim 1 , wherein said composition is administered via an enteral route.
4. The method of claim 1 , wherein said composition is administered up to twice daily, up to once daily, up to once every other day, up to once every third day, up to twice every week, up to once every week and up to once every other week and up to once every month.
5. The method of claim 1 , wherein said composition is administered to a subject in need thereof every time at a dosage level selected from the group consisting of: 0.1-1 mg/kg, 0.1-40 mg/kg, 1-20 mg/kg, 1-10 mg/kg, 3-20 mg/kg and 1-3 mg/kg.
6. The method of claim 1 , wherein the lipocalin mutein is capable of inhibiting binding of hepcidin to a hepcidin specific monoclonal antibody having the variable light chain region shown in SEQ ID No: 6 and the variable heavy chain region shown in SEQ ID No: 7.
7. The method of claim 1 , wherein the lipocalin mutein competes for binding to hepcidin with an antibody having the variable light and heavy chain regions shown in SEQ ID No: 6 and 7, respectively.
8. The method of claim 1 , wherein the lipocalin mutein has at least a 75% sequence identity or homology to SEQ ID NO: 1.
9. The method of claim 1 , wherein the lipocalin mutein is conjugated to a compound that extends the serum half-life of the mutein.
10. The method of claim 9 , wherein the compound that extends the serum half-life is selected from the group consisting of a polyalkylene glycol molecule, a hydroethylstarch, a protein domain, a Fc part of an immoglobulin, a CH3 domain of an immoglobulin, a CH4 domain of an immoglobulin, an albumin-binding peptide, and an albumin-binding protein.
11. The method of claim 9 , wherein the lipocalin mutein is capable of increasing the bioavailability of iron.
12. The method of claim 9 , wherein the polyalkylene glycol is polyethylene (PEG) or an activated derivative thereof.
13. The method of claim 9 , wherein the polyethylene (PEG) is 30 kiloDaltons in molecular weight.
14. The method of claim 10 , wherein the polyalkylene glycol is polyethylene (PEG) or an activated derivative thereof.
15. The method of claim 10 , wherein the polyethylene (PEG) is 30 kiloDaltons in molecular weight.
16. A highly concentrated, stable pharmaceutical formulation of at least one lipocalin mutein having binding affinity to hepcidin, which is capable of increasing the bioavailability of iron in a subject in need thereof, comprising:
a. about 50 to 350 mg/ml of the lipocalin mutein;
b. about 1 to 100 mM of a buffering agent providing a pH of 5.5 to 8;
c. about 1 to 500 mM of a stabilizer or a mixture of two or more stabilizers;
d. about 0.01 to 0.08% of a non-ionic surfactant; and
e. an effective amount of at least one hyaluronidase enzyme, wherein the lipocalin mutein has the same amino acids as the mutein set forth in SEQ ID NO: 1 at two or more positions corresponding to positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103,106, 125, 127, 132, and 134 of the linear polypeptide sequence of the mature hNGAL, wherein the lipocalin mutein or fragment thereof is capable of increasing the bioavailability of iron in the subject, wherein said fragment lacks at least one of the N-terminal and/or C-terminal amino acids compared to said lipocalin mutein.
17. The formulation according to claim 16 for use in a method of treating a disorder which is amenable to treatment with a lipocalin mutein or fragments or variants thereof capable of increasing the bioavailability of iron in a subject in need thereof, comprising the step of administering to the subject an amount effective to treat the said disorder.
18. A kit comprising one or more vials containing the formulation according to claim 16 and an injection device for subcutaneous administration of the formulation to a patient.
19. The method of claim 1 , wherein the lipocalin mutein has at least 90% sequence identity or homology to SEQ ID NO: 1.
20. The method of claim 1 , wherein the lipocalin mutein has the same amino acids as the mutein set forth in SEQ ID NO: 1 at the positions corresponding to positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 106, 125, 127, 132, and 134 of the linear polypeptide sequence of the mature hNGAL.
21. The method of claim 1 , wherein the lipocalin mutein has a sequence as set forth in SEQ ID NO: 1.
22. The method of claim 1 , wherein the lipocalin mutein does not bind to Fe-enterobactin.
23. A method of antagonizing hepcidin binding to its receptor in a subject, comprising administering to a subject a lipocalin mutein, or a fragment thereof having binding affinity to hepcidin, wherein the lipocalin mutein has the same amino acid(s) as the mutein set forth in SEQ ID NO: 1 at two or more positions corresponding to positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 106, 125, 127, 132, and 134 of the linear polypeptide sequence of the mature hNGAL, wherein the lipocalin mutein or fragment is capable of increasing the bioavailability of iron in the subject, wherein said fragment lacks at least one of the N-terminal and/or C-terminal amino acids compared to said lipocalin mutein.